The Supreme Court Will Hear Myriad Case Again
The Supreme Court has granted certiorari to review the AMP v. USPTO case relating to the Myriad patents on the BRCA1 and BRCA2 genes. The Court agreed to review the case only on the issue of the validity of patent genes under 35 U.S.C. §101. This is the second time that the Supreme Court has granted cert on the Myriad case, the first being in March when the Court sent the case back down to the Federal Circuit for reconsideration in light of Mayo v. Prometheus.